Predicting the Long-term Outcomes of Biologics in Psoriasis Patients using Machine Learning.
Despite the vast amount of data on the efficacy of biologics in psoriasis treatment, therapeutic decision-making is still based on a trial-and-error approach. In a real world setting over 50% of patients needing dose adjustment during therapy and 20-50% of patients experiencing a relapse of the disease requiring a switch to another medication.